Clinical Trials
21 trialsNCT03589729 2026-05-22
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02115295 2026-05-20
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03263572 2026-05-20
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01424982 2026-04-15
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03147612 2026-02-17
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00390793 2025-02-17
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003407 2023-02-02
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
Phase 2 Withdrawn
NCT00015951 2019-10-17
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
University of Maryland, Baltimore
Phase 2 Completed
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01019317 2016-03-15
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01670084 2015-10-30
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Phase 2 Withdrawn
NCT00955916 2014-06-27
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00054327 2013-07-24
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00334074 2013-07-17
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Baylor Research Institute
Phase 2 Completed
NCT00002800 2013-07-03
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002502 2013-06-27
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002598 2013-06-25
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00023920 2013-01-23
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00002833 2012-07-30
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00047021 2010-06-11
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00594555 2008-10-31
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
University of Cincinnati
Phase 2 Withdrawn